Navigation Links
Celtic Pharma Holdings Announces Investment in Novacta Biosystems Limited
Date:7/5/2009

ST PETER PORT, Guernsey and LONDON, July 6 /PRNewswire/ --

- GBP13.1 Million Funding to Drive Novel Antibiotics Platform Addressing Areas of Major Unmet Need, Including Hospital Acquired Infections C. Difficile and MRSA

Celtic Pharma Holdings Advisors LLP ("CPHA"), the advisor to the second Celtic Pharma fund, Celtic Pharma Holdings II LP ("CP2"), today announces its investment in a majority shareholding in Novacta Biosystems Limited ("Novacta"), which is developing a portfolio of antibiotics. The total being raised is GBP13.1m ($21.6m), payable against pre-agreed milestones. As part of this investment certain existing investors are re-investing.

Novacta is a UK-based company developing novel, naturally-derived products known as 'lantibiotics' as potential drugs. Lantibiotics have potent anti-infective properties but have historically been underexploited owing to a lack of research tools, a challenge that Novacta has successfully addressed through its proprietary technology platform. The most advanced programme will enter the clinic next year to treat infections caused by Clostridium difficile ("C. difficile"). The Wellcome Trust has provided in the order of GBP4m of translational funding to Novacta since 2004 for the development of the platform technology and more recently the C. difficile programme.

New anti-infective drugs are needed to target C. difficile without depleting other beneficial bacteria in the gut and preclinical data show that Novacta's lead lantibiotics selectively kill C. difficile with less disturbance of normal gut bacteria than seen with existing drugs. C. difficile infections (CDIs) are a serious problem: the number of cases grew by 22 percent in the UK last year, accounting for twice as many deaths as MRSA.

Novacta's pipeline also includes programmes targeting other areas of unmet medical need in bacterial infection. These include novel promising lantibiotic candidates in pre-clinical testing for the treatment of Gram-positive infections including MRSA and novel broad spectrum bacteriocins for the treatment of both Gram-positive and Gram-negative infections.

Following the completion of the investment, Novacta will appoint Dr. Richard Garraway and Dr. Bob Milsted, both partners of CPHA, to its Board of Directors. In a further Board change, the Chairman Dr. Andrew Sandham will retire from the Board on completion and will be replaced by Dr. Andy Richards. The new directors bring significant drug development, financial and corporate development experience to Novacta.

Commenting on the investment, John Mayo, Managing Partner of CP2 said: "The urgent need for new antibiotics is well known, Novacta represents a real opportunity to meet this significant unmet medical need in C. difficile infection, MRSA and related Gram-positive infections and Gram-negative infections, such as E. coli and Salmonella. Our investment in Novacta fits our model of taking a majority position in high quality companies with well differentiated technologies and bringing both funding and additional commercial, regulatory, drug development and manufacturing experience to increase both the probability of success and the value of the products. We are looking forward to working with the dynamic management team at Novacta under Tony Sedgwick, producing important new antibiotics and a great return for existing Novacta shareholders and Celtic Pharma investors alike."

Stephen Parker, a Partner in CP2 added: "This is the second in a series of major investments in high-quality UK biotech companies. We were delighted to see the announcement from the UK Government this week of the creation of the Innovation Investment Fund-of-funds to invest in technology-based businesses and we look forward to helping the Government fulfil its ambitions in the UK life science sector as we continue to invest. CP2 is currently assessing several further opportunities to invest in attractive, high-growth potential UK companies."

Dr. Tony Sedgwick, Chief Executive Officer of Novacta said: "We have worked closely with CP2 to consummate this investment, one of the largest in Europe this year. We have made great progress with our technology platform and pipeline and now have the funds to accelerate development. In particular, access to the expertise at CP2 will ensure that we develop drugs to the standards looked for by big pharma and maximise their commercial value. I would like to thank Andy Sandham for his leadership and wise counsel as our outgoing Chairman and welcome Andy Richards to the role. We are also pleased that Richard and Bob are joining the Board from CP2."

Notes to Editors

About Celtic Pharma Holdings Advisors LLP

Celtic Pharma Holdings Advisors is a global private equity fund management partnership focused on the biotechnology and pharmaceutical industries. Our second fund, Celtic Pharma Holdings II LP, invests in companies which own proven technology platforms and early clinical development-stage pharmaceutical programmes and directs the management of these programmes through their development prior to sale at proof of concept with appropriate efficacy and safety data (usually at end of Phase II clinical trials).

CP2 has already attracted investment from sovereign wealth funds, pension funds and high net worth individuals from many countries and continues to raise further capital. For further information, please visit our website at www.celticpharmaholdings.com.

About Novacta Biosystems Limited

Novacta is a UK-based biotechnology company that specialises in the discovery and development of potential treatments for infectious diseases. Novacta's lead programmes are centred around a class of small peptide molecules called lantibiotics, a drug class that, until now, has been underexploited due to the lack of adequate research tools. Novacta's lantibiotic platform has given rise to a number of potential drug candidates, including those in the C. difficile programme. Other programmes include one targeting methicillin-resistant Staphylococcus aureus (MRSA) infection and others targeting Gram-negative infections. For further information, please visit our website at www.novactabio.com.

About Lantibiotics

Lantibiotics are a naturally occurring class of antibiotic peptide compounds found in a large number of bacteria. They take their name from the lanthionine amino acids found within their structure ( lanthionine-containing antibiotics). Lantibiotics have demonstrated potential to treat infections caused by agents such as C. difficile and MRSA. Conventional medicinal chemistry has been unable to manipulate the structure of the naturally occurring compounds into the optimised forms that have the potential to treat human disease. However, Novacta's proprietary technologies allow the structural manipulation and optimisation of activity which is necessary to unlock the potential of this novel and under-exploited class of compounds.

    Please contact with enquiries:

    Celtic Pharma Holdings Advisors
    John Mayo / Stephen Parker
    LLP
    Tel: +44(20)7291-5456
    stephen.parker@celticpharmaholdings.com

    Novacta Biosystems Ltd.
    Georg Buchner
    VP, Corporate & Business Development
    Tel: +44(0)1707-356130
    georg.buchner@novactabio.com

    Citigate Dewe Rogerson Limited
    David Dible / Chris Gardner
    Tel: +44(0)20-7638-9571
    david.dible@citigatedr.co.uk / chris.gardner@citigatedr.co.uk



'/>"/>
SOURCE Celtic Pharma Holdings Advisors LLP
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Neurobiological Technologies Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009
2. iCardiac Selected by Top 10 Pharmaceutical Company
3. WuXi PharmaTech Receives Award from BASF
4. Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease
5. NeoStem Raises Additional Funds from Principals of Suzhou Erye Pharmaceuticals Company Ltd. and U.S. Institutional and Private Investors, Bringing the Total Recent Financings to Over $15 Million; Funds Will Support Expansion Activities in the United State
6. Particle Sciences and Microfluidics Collaborate to Share Formulation and Nanotechnology Expertise for Pharmaceutical Drug Product Development, Analysis and Commercialization
7. Rib-X Pharmaceuticals, Inc. Appoints Dr. Russell Greig to Board of Directors
8. OncoGenex Pharmaceuticals Added to Russell Indexes
9. Asia Debut for Money-Saving Pharma-Packaging Machines from Ireland
10. Pharmaxis Closes Share Purchase Plan
11. ADVENTRX Pharmaceuticals Announces Plans for Remainder of 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... - BioAmber Inc. (NYSE: BIOA ), a leader ... & Co. Ltd., its partner in the ... an additional CDN$25 million in the joint venture for ... to 40%.  Mitsui will also play a stronger role ... Sarnia , providing dedicated resources alongside BioAmber,s ...
(Date:2/10/2016)... ASAE is introducing a hybrid membership model ... the option of joining or renewing through an organizational ... staff size, every employee in any size association or ... all available member benefits.   John H. ... options will allow organizations of any size and their ...
(Date:2/10/2016)... -- Matchbook, Inc., a company specializing in procurement and ... today the appointment of Jim Shuman ... 25 years of experience in supply chain, logistics ... decades in executive level roles as the SVP ... most recently headed global logistics and procurement at ...
(Date:2/10/2016)... ... February 10, 2016 , ... SonaCare Medical, LLC ... support program, Sonalinkā„¢ remote monitoring. The inaugural launch of this new technology occurred ... connecting Dr. Samuel Peretsman to a HIFU technical expert at SonaCare Medical headquarters. ...
Breaking Biology Technology:
(Date:2/2/2016)... , Feb. 2, 2016 This ... the bioinformatic market by reviewing the recent advances ... tools that drive the field forward. Includes forecast ... Identify the challenges and opportunities that exist ... and software solution developers, as well as IT ...
(Date:2/1/2016)... 2016 Rising sales of consumer ... touchfree intuitive gesture control market size ... of consumer electronics coupled with new technological advancements to ... size through 2020   --> ... technological advancements to drive global touchfree intuitive gesture control ...
(Date:1/25/2016)... , Jan. 25, 2016   Unisys Corporation (NYSE: ... John F. Kennedy (JFK) International Airport, New York City ... (CBP) identify imposters attempting to enter the United States ... to them. pilot testing of the system at ... three terminals at JFK during January 2016. --> pilot ...
Breaking Biology News(10 mins):